Maynard Um
-
-
-
-
-
-
-
Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines
-
-
-
-
-
-
-
Guggenheim Reiterates Buy Rating on Merck (MRK)
-
-
-
-
-
-
-
Moderna (MRNA) call put ratio 1 calls to 1.9 puts after INTerpath-001 trial results
-
-
-
-
-
-
-
Piper Sandler Reiterates Overweight Rating on Moderna (MRNA) Following FDA Approval of mRNA Flu Vaccine
-
-
-
-
-
-
-
Moderna (MRNA) Tops Q2 EPS by 6c, Beats on Revenue
-
-
-
-
-
-
-
Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
-
-
-
-
-
-
-
Moderna outlines three-horizon growth strategy at 2026 Science Day
-
444,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

